TDP1

Tyrosyl-DNA phosphodiesterase 1 · Q9NUW8 · TDP1 on Sugi Atlas →

2,680,097 patent compounds predicted against TDP1, 1,581,821 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3446	0.62	14/20
Meclocycline (SCHEMBL3445)	0.59	14/20
SCHEMBL4015	0.73	13/20
Methacycline (SCHEMBL4014)	0.70	13/20
Methacycline (SCHEMBL4016)	0.70	13/20
Cephaloridine (SCHEMBL3936)	1.00	12/20
Doxycycline Anhydrous (SCHEMBL3156)	0.70	10/20
Doxycycline Anhydrous (SCHEMBL3155)	0.69	10/20
Cefazolin (SCHEMBL2841)	0.86	9/20
Cefazolin (SCHEMBL2842)	0.86	9/20
Demeclocycline (SCHEMBL3252)	0.71	9/20
Demeclocycline (SCHEMBL3253)	0.71	9/20
Oxytetracycline (SCHEMBL2898)	0.70	9/20
Minocycline (SCHEMBL4042)	0.70	9/20
Minocycline (SCHEMBL4043)	0.70	9/20
Oxytetracycline (SCHEMBL2899)	0.70	9/20
Minocycline (SCHEMBL2538)	0.68	9/20
Diphenylamine (SCHEMBL229)	0.92	8/20
Minocycline (SCHEMBL2537)	0.71	8/20
Minocycline (SCHEMBL2539)	0.71	8/20

Clinical trials — most relevant to TDP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer	PHASE2	COMPLETED
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	PHASE2	RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders	PHASE1	RECRUITING
[18F]ACI-19626 PET in TDP-43 Proteinopathies	EARLY_PHASE1	RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Exposure to Neurotoxins as Risk Factors for ALS	nan	COMPLETED
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Vascular Senescence and Atherosclerotic Plaque Vulnerability	nan	RECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia	nan	UNKNOWN
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Identification of New FTLD Genes	nan	UNKNOWN
Telomere and Telomerase	nan	WITHDRAWN
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
Chromosomal Translocations in Chandigarh Police	nan	COMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TDP1 binder may also engage these)

Protein	Name	Similarity
Q8BJ37	—	1.000	Q8BJ37 →
Q4G056	—	0.994	Q4G056 →
Q9VQM4	—	0.982	Q9VQM4 →
Q8H1D9	—	0.981	Q8H1D9 →
Q4KLT3	—	0.979	Q4KLT3 →
O88509	—	0.979	O88509 →
Q2VPA6	—	0.975	Q2VPA6 →
F6QZ15	—	0.974	F6QZ15 →
Q5M9G7	—	0.974	Q5M9G7 →
P97386	—	0.974	P97386 →
Q5ZLG3	—	0.973	Q5ZLG3 →
Q4KWH8	—	0.973	Q4KWH8 →
F1RA39	—	0.973	F1RA39 →
Q5ZJM3	—	0.972	Q5ZJM3 →
Q8N1G2	—	0.972	Q8N1G2 →
P54276	—	0.972	P54276 →
LIG3	DNA ligase 3	0.972	landscape →
Q5U2Z5	—	0.972	Q5U2Z5 →
Q803R5	—	0.972	Q803R5 →
Q6DDT4	—	0.972	Q6DDT4 →
Q95K79	—	0.971	Q95K79 →
Q5R981	—	0.971	Q5R981 →
Q9DBC3	—	0.971	Q9DBC3 →
P51432	—	0.971	P51432 →
Q8GT06	—	0.971	Q8GT06 →
Q9SRU7	—	0.971	Q9SRU7 →
Q02395	—	0.971	Q02395 →
Q68EP9	—	0.971	Q68EP9 →
Q7SXA9	—	0.971	Q7SXA9 →
Q96BT7	—	0.970	Q96BT7 →